Written & reviewed by Dr Bahl
Dr Bahl is an experienced doctor whose career has taken an unusually broad path — beginning as an anatomist, moving into surgery, and ultimately working as a specialist doctor in urology. That journey gives him a rare depth of understanding of the body's structures and how conditions like chronic prostatitis develop and persist. At Shockwave Revibe he leads all shockwave therapy assessments and treatment protocols, bringing that clinical background to every patient consultation.
Men's Health Urology Shockwave TherapyChronic prostatitis is one of the most common — and most frustrating — conditions in men's health. It accounts for roughly 8% of all urology outpatient visits, yet many men spend years cycling through antibiotics, pain relief, and lifestyle changes with limited or temporary benefit.
If you've been living with pelvic pain, urinary discomfort, or pain during or after ejaculation, you'll know how much it can affect daily life, sleep, relationships, and mental wellbeing. The difficulty is that this condition is poorly understood by many general practitioners, and the standard treatment pathways often leave men with incomplete relief.
Shockwave therapy is emerging as one of the most clinically supported non-invasive options available for chronic prostatitis — and the evidence behind it is genuinely compelling. This article explains what the research shows, how Dr Bahl uses it in practice at Shockwave Revibe, and what you can realistically expect.
Understanding Chronic Prostatitis
Chronic prostatitis encompasses a spectrum of conditions. The most prevalent — and often the most difficult to treat — is Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS), which accounts for over 90% of all prostatitis diagnoses. It is not caused by a bacterial infection, which is why antibiotics are frequently ineffective.
Bacterial prostatitis (Type I & II)
Caused by a bacterial infection. Typically treated with antibiotics. Accounts for fewer than 10% of cases.
CP/CPPS (Type III) — most common
Non-bacterial. Inflammation-driven, often with no identifiable pathogen. Accounts for over 90% of all prostatitis cases.
Type IIIA — inflammatory
White blood cells present in prostatic secretions. May involve an immune-mediated inflammatory response.
Type IIIB — non-inflammatory
No white blood cells detected. Often involves pelvic floor muscle dysfunction and central sensitisation.
CP/CPPS is estimated to affect between 8% and 25% of the male population, with some lifetime prevalence figures suggesting up to 50% of men will experience symptoms at some point. Despite this, it remains notoriously difficult to manage — no single treatment works for every patient, and the complex, multi-factorial nature of the condition makes a one-size-fits-all approach ineffective.
Symptoms: More Than Just Pelvic Pain
The symptom burden of chronic prostatitis extends well beyond the prostate itself, and this is precisely why it has such a significant impact on quality of life:
- Pelvic, perineal, or rectal pain — often described as a dull ache or pressure that can be constant or intermittent
- Pain during or after ejaculation — one of the most distressing symptoms, directly affecting sexual relationships
- Urinary urgency, frequency, or incomplete emptying
- Pain in the lower back, inner thighs, or tip of the penis
- Erectile dysfunction — frequently co-existing with CP/CPPS
- Sleep disturbance, anxiety, depression, and reduced quality of life
Many men suffer in silence for months or years before seeking specialist help — in part because the condition is difficult to discuss, and in part because initial treatments often provide little relief.
Why Standard Treatments Often Fall Short
Antibiotics are frequently prescribed as a first response to prostatitis, yet for the overwhelming majority of cases (CP/CPPS), there is no bacterial infection to treat. Alpha-blockers may help with urinary symptoms, but do little for pain. Anti-inflammatory medications provide temporary relief without addressing the underlying problem. Pelvic floor physiotherapy can be beneficial but requires sustained commitment and specialist access.
This is the gap that shockwave therapy increasingly fills — a non-invasive, evidence-backed intervention that targets the biological mechanisms driving chronic pelvic pain, rather than simply masking symptoms.
How Shockwave Therapy Works for Chronic Prostatitis
Low-intensity extracorporeal shockwave therapy (LI-ESWT) delivers precisely calibrated acoustic energy pulses to the prostate and surrounding pelvic tissues. Several mechanisms are thought to explain its effect:
1. Disruption of chronic inflammation
Shockwave energy triggers a controlled biological response in the treated tissue, interrupting the cycle of chronic neurogenic inflammation that underlies CP/CPPS. This is fundamentally different from anti-inflammatory medication, which suppresses inflammation systemically rather than at source.
2. Neovascularisation — improved blood supply
LI-ESWT stimulates the formation of new blood vessels (angiogenesis) within the prostate and pelvic floor tissues. Improved local circulation supports tissue repair and reduces the ischaemic component of chronic pelvic pain.
3. Pain signal modulation
Shockwave therapy has been shown to interfere with the peripheral and central pain pathways responsible for the persistent pelvic pain characteristic of CP/CPPS. This helps explain why pain relief can be noticeable within just a few sessions.
4. Pelvic floor tissue effects
In many men with CP/CPPS, pelvic floor muscle dysfunction plays a significant role. Shockwave energy helps reduce myofascial tension and trigger point activity in the pelvic floor — an area that conventional prostate-focused treatments often overlook entirely.
What the Clinical Evidence Actually Shows
The evidence base for shockwave therapy in chronic prostatitis has grown substantially. Below is an honest summary of what peer-reviewed research demonstrates.
Randomised controlled trial — P100 device, 83 patients (Prostate Cancer and Prostatic Diseases, 2026)
In this sham-controlled trial, 78.4% of men receiving ESWT achieved a clinically meaningful response (defined as a reduction of 6 or more points on the NIH-CPSI scale) at four weeks, compared to just 25% in the placebo group. NIH-CPSI scores dropped from a median of 35 at baseline to 13 at week four — and improvement was sustained at week eight. A statistically significant difference that left little ambiguity about the treatment's effect.
Prostate Cancer and Prostatic Diseases, published January 2026 — Nature Publishing Group
215-patient study — refractory CP/CPPS, 12-month follow-up (PMC8396816)
Among 215 patients who had not responded to prior treatments, ESWT produced a 31–54% reduction in total NIH-CPSI scores over 12 months. Pain domain scores improved by more than twofold. Urinary symptoms improved by 27–51%, and quality-of-life scores also showed meaningful gains. Erectile function improved by approximately 1.3-fold on the IIEF-5 by month 12.
PMC8396816 — International Journal of Urology
Meta-analysis — 12 RCTs, 838 patients (Chinese study, PubMed PMID 32233224)
This large meta-analysis of 12 randomised controlled trials found that men treated with ESWT had a dramatically higher rate of overall effectiveness compared to controls (OR = 8.75, p < 0.00001), alongside significantly lower NIH-CPSI symptom scores. The finding held across different treatment protocols and device types.
PubMed PMID 32233224 — Zhonghua Nan Ke Xue
Systematic review & meta-analysis — Neurourology and Urodynamics (2024)
Labetov et al.'s comprehensive 2024 review concluded that ESWT can be recommended for CP/CPPS treatment based on its non-invasiveness, safety profile, and successful clinical results demonstrated across available studies. The authors noted that it offers a meaningful option for a condition where existing therapies regularly fail to provide relief.
Labetov I et al., Neurourology and Urodynamics, June 2024. DOI: 10.1002/nau.25524
Meta-analysis — systematic review of non-bacterial prostatitis (PMC7769278)
ESWT was significantly associated with reduced pain (mean difference −3.93 points, p < 0.001), improved urinary score (p < 0.001), better quality of life (p < 0.001), and a 5.45-point improvement in NIH-CPSI score after 12 weeks compared to controls. The authors concluded that ESWT is both efficacious and safe for chronic non-bacterial prostatitis.
PMC7769278 — PLOS ONE, December 2020
Long-term follow-up study — 48 weeks post-treatment (PMC10612526, 2023)
This Lithuanian study followed 28 patients for 48 weeks after completing ESWT. Meaningful improvements in VAS pain scores, NIH-CPSI, and erectile function (IIEF-5) were maintained throughout. The greatest progress occurred at week 24, with stable results persisting at weeks 36 and 48 — suggesting that the benefits of shockwave therapy are not merely short-lived.
Open Medicine, published October 2023. DOI: 10.1515/med-2023-0832
"Chronic prostatitis is one of those conditions where men often feel they've run out of options. The shockwave therapy evidence is more substantial than many people realise — and for men who've tried other approaches without lasting relief, it represents a genuinely different mechanism of action."
— Dr Bahl, Shockwave Revibe
Treatments Offered at Shockwave Revibe Under Dr Bahl
Dr Bahl takes an individualised approach to each patient. At Shockwave Revibe, treatment is always structured around a thorough clinical assessment — never templated or rushed.
LI-ESWT for Chronic Prostatitis / CP/CPPS
The primary treatment for chronic prostatitis and pelvic pain at Revibe. Using a medically certified shockwave device, Dr Bahl delivers precisely calibrated pulses to the perineal and pelvic region. Protocol parameters — including energy flux density, pulse count, and session frequency — are tailored to the individual's symptom profile and response to treatment.
Shockwave Therapy for Concurrent Erectile Dysfunction
Erectile dysfunction is a common companion to CP/CPPS, affecting a meaningful proportion of men with the condition. Where appropriate, Dr Bahl incorporates ED-focused shockwave protocols alongside prostatitis treatment. Clinical evidence confirms that LI-ESWT improves penile haemodynamics and erectile function independently — making this a practical combined approach for men with both conditions.
Pelvic Pain Assessment and Structured Treatment Planning
Dr Bahl's background as an anatomist and urologist means he approaches pelvic pain with a deep understanding of the structures involved — the prostate, pelvic floor, surrounding fascia, and neurovascular supply. This informs a treatment plan that addresses the condition in its full complexity rather than focusing narrowly on the prostate alone.
Progress Review and Protocol Adjustment
Outcomes are reviewed at regular intervals using validated scoring tools (NIH-CPSI, VAS, IIEF). Treatment protocols are adjusted based on response, and Dr Bahl will always provide an honest assessment of how you are progressing — including, where relevant, whether additional or alternative approaches may be beneficial.
How Shockwave Therapy Compares
| Approach | Pain relief | Urinary symptoms | Invasiveness | Evidence in CP/CPPS |
|---|---|---|---|---|
| Antibiotics | Minimal (non-bacterial cases) | Minimal | None | Only for bacterial prostatitis |
| Alpha-blockers | Modest | Moderate | None | Helps urinary symptoms only |
| NSAIDs / pain relief | Short-term only | None | None | Symptomatic management only |
| Shockwave Therapy (LI-ESWT) Recommended | Strong — sustained relief in clinical trials | Meaningful improvement | Non-invasive | Multiple RCTs & meta-analyses |
| Pelvic floor physiotherapy | Moderate | Moderate | Non-invasive | Good evidence — can complement ESWT |
| Surgical / invasive procedures Rarely indicated | Variable | Variable | Highly invasive | Not standard for CP/CPPS |
Who is Most Likely to Benefit?
Shockwave therapy is particularly well-suited to men in the following situations, though a proper assessment with Dr Bahl is always the starting point:
- Men with a diagnosis of CP/CPPS (Type IIIA or IIIB) who have not found lasting relief through antibiotics or other standard treatments
- Men experiencing significant pelvic, perineal, or ejaculatory pain that is affecting quality of life
- Men with urinary symptoms — urgency, frequency, or incomplete emptying — alongside pelvic pain
- Men who also have erectile dysfunction and want a treatment that addresses both conditions simultaneously
- Men who want to avoid long-term reliance on pain medication or repeated antibiotic courses
- Men with long-standing symptoms who have been told there is nothing more that can be done
What to Realistically Expect
We do not promise outcomes that the evidence cannot support. Based on the clinical literature and Dr Bahl's direct experience, here is what men who respond to treatment typically report:
- Reduction in pelvic and perineal pain — often noticeable within the first 2–4 sessions
- Less pain during or after ejaculation, improving sexual comfort and confidence
- Improved urinary flow and reduced urgency or frequency
- Better sleep, reduced anxiety around symptoms, and improved daily function
- Improvement in erectile function in men where ED co-exists
- Sustained benefits over months — not just short-term relief that fades
As with any treatment, responses vary. Men with shorter symptom duration and less complex presentations tend to respond most strongly. Dr Bahl will give you an honest view of your likely trajectory from the outset.